Literature DB >> 8035311

Cardiovascular and behavioral responses to nicotinic agents administered intrathecally.

I M Khan1, P Taylor, T L Yaksh.   

Abstract

We have examined the role of the spinal nicotinic receptors in mediating cardiovascular and behavioral responses in conscious rats. Intrathecal administration of nicotinic agonists to the lumbosacral region of the spinal cord caused a dose-dependent increase in systolic blood pressure, heart rate and a nociceptive (behavioral) response. The order of potencies for the pressor response was l-nicotine > or = cytisine > N-methylcarbamylcholine > or = dimethylphenylpiperazinium > d-nicotine. However, cytisine was the most potent in producing the heart rate increase and nociceptive response. Unlike the other agonists, cytisine also exhibited marked desensitization of the three responses upon repeated administration. The effects of nicotine were antagonized in a dose-dependent fashion by mecamylamine, hexamethonium, alpha-lobeline, dihydro-beta-erythroidine and methyllycaconitine. By contrast, cytisine-induced responses were blocked effectively by mecamylamine and methyllycaconitine, but not by alpha-lobeline or dihydro-beta-erythroidine. However, when alpha-lobeline or dihydro-beta-erythroidine antagonism of the pressor response to cytisine was monitored during the initial minute following intrathecal administration, both antagonists significantly inhibited the response. The competitive ganglionic blocker, trimethaphan, or the elapid alpha-toxin, alpha-bungarotoxin, when administered intrathecally, had no effect on nicotine- or cytisine-elicited responses. The cardiovascular responses to intrathecal nicotine and cytisine have two components. The first is likely mediated through direct sympathetic output and desensitizes rapidly to cytisine, the second is coupled indirectly to the nociceptive response and shows a diminished capacity for rapid desensitization. Agonist and antagonist specificities indicate that the spinal nicotinic receptor differs from those in ganglia and those characterized in brain to date. Although antagonist specificity of the blockade of nicotine and cytisine elicited responses differ, this may be due to the unique desensitization capacity of cytisine rather than an action mediated by distinct receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035311

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Nicotinic actions on neurones of the central autonomic area in rat spinal cord slices.

Authors:  A Bordey; P Feltz; J Trouslard
Journal:  J Physiol       Date:  1996-11-15       Impact factor: 5.182

2.  Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release.

Authors:  P B Clarke; M Reuben
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

3.  Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology.

Authors:  Tracey Young; Shannon Wittenauer; Renee Parker; Michelle Vincler
Journal:  Eur J Pharmacol       Date:  2008-06-11       Impact factor: 4.432

4.  Elimination of rat spinal substance P receptor bearing neurons dissociates cardiovascular and nocifensive responses to nicotinic agonists.

Authors:  Imran M Khan; Chris V Wart; Erin A Singletary; Shanaka Stanislaus; Tom Deerinck; Tony L Yaksh; Morton P Printz
Journal:  Neuropharmacology       Date:  2007-10-17       Impact factor: 5.250

5.  Short- and long-term enhancement of excitatory transmission in the spinal cord dorsal horn by nicotinic acetylcholine receptors.

Authors:  Jonathan R Genzen; Daniel S McGehee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

6.  Patch-clamp characterization of nicotinic receptors in a subpopulation of lamina X neurones in rat spinal cord slices.

Authors:  A Bordey; P Feltz; J Trouslard
Journal:  J Physiol       Date:  1996-02-01       Impact factor: 5.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.